Product Name :
PCI-27483
Description:
PCI-27483 is a FVIIa/tissue factor inhibitor, with antitumour effects.
CAS:
871266-63-6
Molecular Weight:
596.57
Formula:
C26H24N6O9S
Chemical Name:
(2S)-2-{2-[5-(6-carbamimidoyl-1H-1,3-benzodiazol-2-yl)-2′,6-dihydroxy-5′-sulfamoyl-[1,1′-biphenyl]-3-yl]acetamido}butanedioic acid
Smiles :
NC(=N)C1=CC2NC(=NC=2C=C1)C1=CC(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=CC(C2=CC(=CC=C2O)S(N)(=O)=O)=C1O
InChiKey:
WDJHHCAKBRKCLW-IBGZPJMESA-N
InChi :
InChI=1S/C26H24N6O9S/c27-24(28)12-1-3-17-18(8-12)32-25(31-17)16-6-11(7-21(34)30-19(26(38)39)10-22(35)36)5-15(23(16)37)14-9-13(42(29,40)41)2-4-20(14)33/h1-6,8-9,19,33,37H,7,10H2,(H3,27,28)(H,30,34)(H,31,32)(H,35,36)(H,38,39)(H2,29,40,41)/t19-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
PCI-27483 is a FVIIa/tissue factor inhibitor, with antitumour effects.|Product information|CAS Number: 871266-63-6|Molecular Weight: 596.{{SARS-CoV-2 PLpro Protein} MedChemExpress|{SARS-CoV-2 PLpro Protein} Protocol|{SARS-CoV-2 PLpro Protein} References|{SARS-CoV-2 PLpro Protein} manufacturer|{SARS-CoV-2 PLpro Protein} Autophagy} 57|Formula: C26H24N6O9S|Chemical Name: (2S)-2-{2-[5-(6-carbamimidoyl-1H-1,3-benzodiazol-2-yl)-2′,6-dihydroxy-5′-sulfamoyl-[1,1′-biphenyl]-3-yl]acetamido}butanedioic acid|Smiles: NC(=N)C1=CC2NC(=NC=2C=C1)C1=CC(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=CC(C2=CC(=CC=C2O)S(N)(=O)=O)=C1O|InChiKey: WDJHHCAKBRKCLW-IBGZPJMESA-N|InChi: InChI=1S/C26H24N6O9S/c27-24(28)12-1-3-17-18(8-12)32-25(31-17)16-6-11(7-21(34)30-19(26(38)39)10-22(35)36)5-15(23(16)37)14-9-13(42(29,40)41)2-4-20(14)33/h1-6,8-9,19,33,37H,7,10H2,(H3,27,28)(H,30,34)(H,31,32)(H,35,36)(H,38,39)(H2,29,40,41)/t19-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 62.{{(S)-(-)-Levamisole} medchemexpress|{(S)-(-)-Levamisole} Neuronal Signaling|{(S)-(-)-Levamisole} Biological Activity|{(S)-(-)-Levamisole} In stock|{(S)-(-)-Levamisole} manufacturer|{(S)-(-)-Levamisole} Epigenetics} 5 mg/mL (104.PMID:24507727 77 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PCI-27483 inhibits the TF:FVIIa-complex induced phosphorylation of ERK1/2 and subsequent induction of c-fos in BxPC3 cells, a human pancreatic adenocarcinoma line that highly expresses TF. Furthermore, PCI-27483 blocks the TF:FVIIa induced secretion of IL8 in both BxPC3 cells and MDA-MB-231 breast cancer cells.|In Vivo:|PCI-27483 shows dose-dependent inhibition of thrombus formation, fibrin accumulation and PT. PCI-27483 (4 mg/kg) shows comparable anticoagulation effects as 2 mg/kg enoxaparin. PCI-27483 (0 and 90 mg/kg, s.c.) results in inhibition of tumor growth in CD1 nu/nu mice implanted with BxPC3 cells.|Products are for research use only. Not for human use.|